(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/057687 A1

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/FI2022/050662

(22) International Filing Date:
04 October 2022 (04.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20216026 04 October 2021 (04.10.2021) FI

(71) Applicant: **TILT BIOTHERAPEUTICS OY** [FI/FI]; c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI).

(72) Inventors: **KUDLING, Tatiana**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **HEMMINKI, Akseli**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **CLUBB, James**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **QUIXABEIRA, Dafne**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **HAVUNEN, Riikka**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI).

(74) Agent: **LAINE IP OY**; Porkkalankatu 24, 00180 Helsinki (FI).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** AN ONCOLYTIC VIRUS VECTOR CODING FOR INTERLEUKIN-7 (IL-7) POLYPEPTIDE

(57) **Abstract:** The present invention provides an oncolytic adenoviral vector comprising a nucleic acid sequence encoding an interleukin 7 (IL-7) polypeptide or a variant thereof as a transgene. The present invention also provides a pharmaceutical composition comprising said oncolytic vector and at least one of the following: physiologically acceptable carriers, buffers, excipients, adjuvants, additives, antiseptics, preservatives, filling, stabilising and/or thickening agents. A particular aim of the present invention is to provide said oncolytic viral vector or pharmaceutical composition for use in the treatment of cancer or tumor, preferably a solid tumor.

WO 2023/057687 A1